Single-bag rapid drug desensitization for chemotherapeutic hypersensitivity reactions: A single-center experience
Allergy and Asthma Proceedings · 2025
DOI: 10.2500/aap.2025.46.250014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy and Asthma Proceedings, 2025. Verfasst von Ozcan Gul und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Desensitization, Immunologic, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Rapid drug desensitization (RDD) is a procedure that provides temporary tolerance to chemotherapeutics for appropriate patients who experience hypersensitivity reactions (HSR), which allow them to continue their treatments. Due to the labor-intensive and time-consuming nature of the commonly used multiple-bag RDD procedure, there is a need to develop an alternative protocol. We aimed to share our experiences with single-bag RDD in patients experiencing HSRs with chemotherapeutics.
Methods
The study was conducted by retrospectively reviewing the files of patients who experienced immediate-type HSRs to chemotherapeutics and underwent single-bag RDD. The severity of HSRs was classified according to the Brown grading system. Prick and/or intradermal skin tests were performed with the relevant agents. The protocols were applied as a single-bag, 12-step process.
Results
The study comprised 46 patients (women/men, 35/11; mean ± standard deviation age, 55.9 ± 11.9 years; 27 HSRs to platinums; 16 HSRs to taxanes; and 3 HSRs to biologic agents). Nine patients (19.6%) had an initial HSR of grade 1, 26 patients (56.5%) had an initial HSR of grade 2, and 11 patients (23.9%) had an initial HSR of grade 3. The skin testing result with the responsible drug was positive in 15 of 42 (35.7%), and the rate of positive responses in patients with grade 1, 2, and 3 initial HSRs was 37.5%, 33.3%, and 40%, respectively. A total of 163 single-bag RDDs procedures were performed, and 17 breakthrough reactions (BTR) occurred during the procedure (five of these reactions [29.5%] were grade 1; nine [53.9%] were grade 2; three [17.6%] were grade 3). Of these BTRs, 16 occurred with platinums and one with rituximab; no BTRs were observed with taxanes. In conclusion, 99.3% of the total 163 single-bag RDD procedures were successfully completed.
Conclusion
Our experience indicates that single-bag RDD can be a safe and effective alternative that saves time and labor in appropriate patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Gul, O., Bayrak Durmaz, M. S., Yıldız, R., Aytekin, F., Beyhan, N., Efe, O., & Bavbek, S. (2025). Single-bag rapid drug desensitization for chemotherapeutic hypersensitivity reactions: A single-center experience. Allergy and Asthma Proceedings. https://doi.org/10.2500/aap.2025.46.250014
Vancouver
Gul O, Bayrak Durmaz MS, Yıldız R, Aytekin F, Beyhan N, Efe O, et al. Single-bag rapid drug desensitization for chemotherapeutic hypersensitivity reactions: A single-center experience. Allergy and Asthma Proceedings. 2025. doi:10.2500/aap.2025.46.250014
BibTeX
@article{Gul2025,
author = {Gul, Ozcan and Bayrak Durmaz, Makbule Seda and Yıldız, Reyhan and Aytekin, Fuat and Beyhan, Nazan and Efe, Orhun and Bavbek, Sevim},
title = {Single-bag rapid drug desensitization for chemotherapeutic hypersensitivity reactions: A single-center experience},
journal = {Allergy and Asthma Proceedings},
year = {2025},
doi = {10.2500/aap.2025.46.250014}
}
EUVIMED